Last $23.43 USD
Change Today -0.01 / -0.04%
Volume 278.9K
EBS On Other Exchanges
Symbol
Exchange
Berlin
As of 4:15 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

emergent biosolutions inc (EBS) Snapshot

Open
$24.51
Previous Close
$23.44
Day High
$24.84
Day Low
$23.17
52 Week High
03/10/14 - $28.48
52 Week Low
08/28/13 - $17.14
Market Cap
878.1M
Average Volume 10 Days
192.3K
EPS TTM
$0.56
Shares Outstanding
37.5M
EX-Date
--
P/E TM
41.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for EMERGENT BIOSOLUTIONS INC (EBS)

emergent biosolutions inc (EBS) Related Businessweek News

No Related Businessweek News Found

emergent biosolutions inc (EBS) Details

Emergent BioSolutions Inc. develops, manufactures, and commercializes immunobiotics such as vaccines and immune globulins that assist the body’s immune system. The company’s biodefense segment develops, manufactures, and commercializes drugs such as BioThrax, a vaccine for the prevention of anthrax, for use against biological agents. Other products in preclinical development include drugs for the treatment of patients after they are exposed to anthrax and botulinum toxin. Emergent’s commercial segment develops products for use against infectious diseases. These include a single-dose typhoid vaccine in phase II clinical development; a hepatitis B vaccine in phase II clinical development, and a group B streptococcus vaccine for women of childbearing age for protection of the fetus and newborn babies, which is in phase I clinical trials. Emergent is also developing chlamydia and meningitis B vaccines. Emergent primarily works for the U.S. Defense and Health & Human Services departments. It has collaboration agreements with the British Health Protection Agency for the development of a human botulinum immune globulin candidate and with Sanofi Pasteur for the development of meningitis B vaccine candidate. The company, which was founded in 1998, is based in Rockville, Maryland.

1,353 Employees
Last Reported Date: 03/10/14
Founded in 1998

emergent biosolutions inc (EBS) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $1.0M
Founder, Executive Chairman and Chairman of S...
Total Annual Compensation: $726.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $694.2K
Executive Vice President and President of Bio...
Total Annual Compensation: $474.8K
Executive Vice President and President of Bio...
Total Annual Compensation: $138.9K
Compensation as of Fiscal Year 2013.

emergent biosolutions inc (EBS) Key Developments

Emergent BioSolutions Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Third Quarter and Second Half of 2014; Revises Earnings Guidance for the Full Year of 2014

Emergent BioSolutions Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. The company reported total revenue for second quarter 2014 of $110.3 million as compared to $82.4 million in 2013. Adjusted net income for second quarter 2014 was $9.4 million as compared to adjusted net income of $11.4 million in 2013. On a GAAP basis, the company reported second quarter 2014 net income of $5.0 million, or $0.13 per share, as compared to $10.5 million, or $0.29 per share, in 2013. Income from operations was $7.862 million against $14.712 million a year ago. Income before provision for income taxes was $7.494 million against $14.737 million a year ago. Net income attributable to Emergent BioSolutions Inc. was $5.029 million against $10.484 million a year ago. This favorable performance in revenue is a result of having the former Cangene operations consolidated with the company for the full quarter following the acquisition in February. Total revenues for the first six months of 2014 were $164.2 million as compared to $125.5 million in 2013. The adjusted net loss for the first six months of 2014 was $5.4 million as compared to adjusted net income of $4.7 million in 2013. On a GAAP basis, the company reported first half 2014 net loss of $15.2 million, or $0.41 per share, as compared to net income of $2.4 million, or $0.07 per share, in 2013. Loss from operations was $17.596 million against income $1.362 million a year ago. Loss before provision for (benefit from) income taxes was $20.947 million against income $1.416 million a year ago. Net loss attributable to Emergent BioSolutions Inc. was $15.207 million against income $2.422 million a year ago. Net cash used in operating activities was $18.426 million against net cash provided by operating activities of $28.202 million a year ago. Purchases of property, plant and equipment was $9.400 million $14.123 million a year ago. The company anticipates third quarter 2014 total revenue of $110 to $125 million. The favorable impact of this change in sales mix, along with anticipated increased international sales of its Biodefense products, should boost its profit contribution in the second half of the year and generate net income in line with its guidance of between $30 million and $40 million on a GAAP basis. As well as the GAAP guidance, they are maintaining the adjusted net income guidance of between $40 million and $50 million that they provided last quarter. The company is increasing its full year 2014 total revenue forecast to $425 to $450 million from $415 to $445 million. This increased range primarily reflects stronger-than-anticipated revenue associated with the Biodefense products acquired from Cangene. The company reaffirmed its net income guidance for the year with a forecast of adjusted net income of between $40 million to $50 million and GAAP net income of between $30 million to $40 million.

Emergent BioSolutions, Inc. Submits Biologics License Application to FDA for Anthrax Immune Globulin Intravenous

Emergent BioSolutions Inc. announced that it has submitted a Biologics License Application to the U.S. Food and Drug Administration (FDA) for Anthrax Immune Globulin Intravenous (Human) [AIGIV] as part of a development contract with the Biomedical Advanced Research and Development Authority (BARDA). AIGIV, which was acquired in the Cangene acquisition completed earlier this year, is being developed as an intravenous therapeutic treatment for inhalation anthrax. AIGIV is a sterile solution of purified human immune globulin G (IgG) containing polyclonal antibodies that targets the anthrax toxins of Bacillus anthracis, the bacteria that causes anthrax disease. It is prepared using plasma collected from healthy, screened donors who have been immunized with BioThrax(R) (Anthrax Vaccine Adsorbed), the only FDA-licensed vaccine for the prevention of anthrax disease. AIGIV was evaluated through studies conducted in animal models of inhalation anthrax and was granted Orphan Drug designation by FDA in 2008.

Emergent Biosolutions Inc. Announces U.S. Food and Drug Administration Issued Complete Response Letter for the New Drug Application of IXINITY

Emergent BioSolutions Inc. announced that the U.S. Food and Drug Administration has issued a complete response letter for the New Drug Application of IXINITY [coagulation factor IX (recombinant)] for the control and prevention of bleeding episodes and perioperative management in adults and children, 12 years old and above, living with Hemophilia B. The complete response letter requested additional analyses of data from completed studies and noted deficiencies in the CMC section of the license application, all of which must be resolved before approval can be granted by FDA. The company plans to engage with the FDA to better ascertain the requirements for approval, following which it will determine its next steps. The company does not anticipate launching the product in 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EBS:US $23.43 USD -0.01

EBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bavarian Nordic A/S kr114.00 DKK 0.00
Bioporto A/S kr2.14 DKK -0.04
Celldex Therapeutics Inc $15.11 USD -0.36
PharmAthene Inc $2.10 USD +0.04
Veloxis Pharmaceuticals A/S kr1.86 DKK -0.01
View Industry Companies
 

Industry Analysis

EBS

Industry Average

Valuation EBS Industry Range
Price/Earnings 64.5x
Price/Sales 2.5x
Price/Book 1.8x
Price/Cash Flow 65.0x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EMERGENT BIOSOLUTIONS INC, please visit www.emergentbiosolutions.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.